Literature DB >> 2784620

Measurement of acute Q-wave myocardial infarct size with single photon emission computed tomography imaging of indium-111 antimyosin.

M L Antunes1, D W Seldin, R M Wall, L L Johnson.   

Abstract

Myocardial infarct size was measured by single photon emission computed tomography (SPECT) following injection of indium-111 antimyosin in 27 patients (18 male and 9 female; mean age 57.4 +/- 10.5 years, range 37 to 75) who had acute transmural myocardial infarction (MI). These 27 patients represent 27 of 35 (77%) consecutive patients with acute Q-wave infarctions who were injected with indium-111 antimyosin. In the remaining 8 patients either tracer uptake was too faint or the scans were technically inadequate to permit infarct sizing from SPECT reconstructions. In the 27 patients studied, infarct location by electrocardiogram was anterior in 15 and inferoposterior in 12. Nine patients had a history of prior infarction. Each patient received 2 mCi of indium-111 antimyosin followed by SPECT imaging 48 hours later. Infarct mass was determined from coronal slices using a threshold value obtained from a human torso/cardiac phantom. Infarct size ranged from 11 to 87 g mean 48.5 +/- 24). Anterior infarcts were significantly (p less than 0.01) larger (60 +/- 20 g) than inferoposterior infarcts (34 +/- 21 g). For patients without prior MI, there were significant inverse correlations between infarct size and ejection fraction (r = 0.71, p less than 0.01) and wall motion score (r = 0.58, p less than 0.01) obtained from predischarge gated blood pool scans. Peak creatine kinase-MB correlated significantly with infarct size for patients without either reperfusion or right ventricular infarction (r = 0.66). Seven patients without prior infarcts had additional simultaneous indium-111/thallium-201 SPECT studies using dual energy windows.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2784620     DOI: 10.1016/0002-9149(89)90041-6

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  7 in total

1.  Myocardial uptake of antimyosin antibody compared with serum myosin light chain I levels in patients with myocardial infarction.

Authors:  M Suehiro; M Fukuchi; H Naruse; T Iwasaki
Journal:  Ann Nucl Med       Date:  1992-02       Impact factor: 2.668

Review 2.  Clinical role of indium-111 antimyosin imaging.

Authors:  S Bhattacharya; A Lahiri
Journal:  Eur J Nucl Med       Date:  1991

Review 3.  Antibody imaging in the evaluation of cardiovascular diseases.

Authors:  B A Khaw; J Narula
Journal:  J Nucl Cardiol       Date:  1994 Sep-Oct       Impact factor: 5.952

Review 4.  Infarct sizing by scintigraphic techniques and nuclear magnetic resonance imaging.

Authors:  E E van der Wall; M G Niemeyer; A de Roos; A V Bruschke; E K Pauwels
Journal:  Eur J Nucl Med       Date:  1990

5.  Quantitative 111In antimyosin antibody imaging to predict the age of myocardial infarction.

Authors:  S Bhattacharya; R Senior; X J Liu; D Jain; A Lahiri
Journal:  Int J Card Imaging       Date:  1992

6.  Transcapillary exchange of indium 111-labeled anticardiac myosin Fab and thallium 201 in isolated reperfused rabbit hearts.

Authors:  D J Meerdink; J A Leppo
Journal:  J Nucl Cardiol       Date:  1994 May-Jun       Impact factor: 5.952

7.  Death, near death, and an antibiotic.

Authors:  Lynne L Johnson
Journal:  J Nucl Cardiol       Date:  2017-09-12       Impact factor: 5.952

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.